MX2015008555A - Combinaciones de un agonista de glp1r y metformina, y uso de los mismos para el tratamiento de la diabetes tipo 2 y otros trastornos. - Google Patents

Combinaciones de un agonista de glp1r y metformina, y uso de los mismos para el tratamiento de la diabetes tipo 2 y otros trastornos.

Info

Publication number
MX2015008555A
MX2015008555A MX2015008555A MX2015008555A MX2015008555A MX 2015008555 A MX2015008555 A MX 2015008555A MX 2015008555 A MX2015008555 A MX 2015008555A MX 2015008555 A MX2015008555 A MX 2015008555A MX 2015008555 A MX2015008555 A MX 2015008555A
Authority
MX
Mexico
Prior art keywords
metformin
diabetes
disorders
combinations
treatment
Prior art date
Application number
MX2015008555A
Other languages
English (en)
Other versions
MX366685B (es
Inventor
Maria Carmen Valcarce Lopez
Adnan M M Mjalli
Bradley Alan Clark
Dharma Rao Polisetti
James C Quada Jr
Robert Carl Andrews
Stephen Thomas Davis
Thomas Scott Yokum
Original Assignee
Vtv Therapeutics Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Vtv Therapeutics Llc filed Critical Vtv Therapeutics Llc
Publication of MX2015008555A publication Critical patent/MX2015008555A/es
Publication of MX366685B publication Critical patent/MX366685B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5383—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C279/00—Derivatives of guanidine, i.e. compounds containing the group, the singly-bound nitrogen atoms not being part of nitro or nitroso groups
    • C07C279/20—Derivatives of guanidine, i.e. compounds containing the group, the singly-bound nitrogen atoms not being part of nitro or nitroso groups containing any of the groups, X being a hetero atom, Y being any atom, e.g. acylguanidines
    • C07C279/24—Y being a hetero atom
    • C07C279/26—X and Y being nitrogen atoms, i.e. biguanides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Endocrinology (AREA)
  • Vascular Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Emergency Medicine (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La presente invención proporciona usos de un agonista del receptor de péptido 1 similar a glucagón, en combinación con metformina. Los usos incluyen tratar la diabetes tipo 2, reducir la glucosa sanguínea y mejorar la efectividad terapéutica de la metformina. La invención también proporciona composiciones farmacéuticas que comprenden un agonista de GLP1R y metformina.
MX2015008555A 2013-01-17 2014-01-14 Combinaciones de un agonista de glp1r y metformina, y uso de los mismos para el tratamiento de la diabetes tipo 2 y otros trastornos. MX366685B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361753567P 2013-01-17 2013-01-17
PCT/US2014/011394 WO2014113357A1 (en) 2013-01-17 2014-01-14 Combinations of a glp1r agonist and metformin and use thereof for the treatment of type 2 diabetes and other disorders

Publications (2)

Publication Number Publication Date
MX2015008555A true MX2015008555A (es) 2016-01-22
MX366685B MX366685B (es) 2019-07-19

Family

ID=50030537

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2015008555A MX366685B (es) 2013-01-17 2014-01-14 Combinaciones de un agonista de glp1r y metformina, y uso de los mismos para el tratamiento de la diabetes tipo 2 y otros trastornos.

Country Status (14)

Country Link
US (1) US20150313908A1 (es)
EP (1) EP2945618B1 (es)
JP (1) JP6445459B2 (es)
KR (1) KR102165434B1 (es)
CN (1) CN104968341B (es)
AU (1) AU2014207748B2 (es)
CA (1) CA2896308C (es)
EA (1) EA201591123A1 (es)
ES (1) ES2687083T3 (es)
HK (1) HK1210424A1 (es)
IL (1) IL239714A0 (es)
MX (1) MX366685B (es)
SG (2) SG10201704716XA (es)
WO (1) WO2014113357A1 (es)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2020002977A (es) 2017-09-22 2020-11-06 Regeneron Pharma Agonistas de receptor de peptido similar al glucagon tipo 1 y usos de los mismos.
MX2020008387A (es) * 2018-05-08 2020-12-11 Vtv Therapeutics Llc Usos terapeuticos de agonistas glp1r.
EP4141008A4 (en) * 2020-04-01 2024-04-17 Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd. PHARMACEUTICALLY ACCEPTABLE ACID SALT OF THE FREE BASE OF A GLP-1 RECEPTOR AGONIST AND METHOD OF MANUFACTURING THE SAME
CN115461344B (zh) * 2020-04-01 2024-01-12 杭州中美华东制药有限公司 一种glp-1受体激动剂的晶型a及其制备方法
US20240199728A1 (en) 2022-09-21 2024-06-20 Regeneron Pharmaceuticals, Inc. Methods of treating obesity, diabetes, and liver dysfunction

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4080472A (en) 1974-03-22 1978-03-21 Societe D'etudes Et D'exploitation De Marques Et Brevets S.E.M.S. Metformin 2-(p-chlorophenoxy)-2-methylpropionate
CA2628506A1 (en) * 2005-11-07 2007-05-18 Elixir Pharmaceuticals, Inc. Combinations of metformin and meglitinide
WO2009111700A2 (en) * 2008-03-07 2009-09-11 Transtech Pharma, Inc. Oxadiazoanthracene compounds for the treatment of diabetes
WO2010114824A1 (en) * 2009-03-30 2010-10-07 Transtech Pharma Inc Substituted azoanthracene derivatives, pharmaceutical compositions, and methods of use thereof
WO2011031620A1 (en) 2009-09-11 2011-03-17 Transtech Pharma, Inc. Solid compositions comprising an oxadiazoanthracene compound and methods of making and using the same
AU2010317995B2 (en) * 2009-11-13 2014-04-17 Sanofi-Aventis Deutschland Gmbh Pharmaceutical composition comprising a GLP-1 agonist, an insulin, and methionine
US20110118180A1 (en) * 2009-11-13 2011-05-19 Sanofi-Aventis Deutschland Gmbh Method of treatment of diabetes type 2 comprising add-on therapy to metformin
US20130040878A1 (en) * 2011-05-13 2013-02-14 Sanofi-Aventis Deutschland Gmbh Pharmaceutical combination for use in the treatment of diabetes type 2 patients

Also Published As

Publication number Publication date
AU2014207748A1 (en) 2015-07-09
JP6445459B2 (ja) 2018-12-26
ES2687083T3 (es) 2018-10-23
AU2014207748B2 (en) 2018-10-11
CA2896308C (en) 2021-11-09
WO2014113357A1 (en) 2014-07-24
CA2896308A1 (en) 2014-07-24
JP2016505039A (ja) 2016-02-18
KR20150104572A (ko) 2015-09-15
EA201591123A1 (ru) 2015-11-30
EP2945618B1 (en) 2018-06-13
CN104968341A (zh) 2015-10-07
HK1210424A1 (en) 2016-04-22
US20150313908A1 (en) 2015-11-05
KR102165434B1 (ko) 2020-10-14
IL239714A0 (en) 2015-08-31
CN104968341B (zh) 2020-06-09
MX366685B (es) 2019-07-19
SG11201504778UA (en) 2015-07-30
EP2945618A1 (en) 2015-11-25
SG10201704716XA (en) 2017-07-28

Similar Documents

Publication Publication Date Title
PH12019501216A1 (en) New compounds as peptidic trigonal glp1/glucagon/gip receptor agonists
MX2016013243A (es) Agonistas peptídicos duales de los receptores de glp-1/glucagón derivados de la exendina-4.
MX2016013244A (es) Derivados de exendina-4 como agonistas peptidicos duales del receptor de glp-1/glucagon.
MX2016013248A (es) Agonistas duales del receptor de glp-1/glucagon derivados de exendina-4.
MX362190B (es) Agonistas duales de glp1/gip o trigonales de glp1/gip/glucagon.
MX2018000362A (es) Derivados de exendina-4 como agonistas peptidicos duales selectivos de los receptores de glp-1/glucagon.
PH12015502042A1 (en) Use of linagliptin in cardio-and renoprotective antidiabetic therapy
PH12015500688A1 (en) Exendin-4 derivatives as dual glp1/glucagon agonists
MX2015015249A (es) Peptidos terapeuticos.
MX343360B (es) Conjugados peptidicos de agonistas del receptor de glp-1 y gastrina y su uso.
MX2016000364A (es) Metodos para tratar o prevenir afecciones oftalmologicas.
MX2013013307A (es) Combinacion farmaceutica para uso en el control glucemico en pacientes con diabetes de tipo 2.
MX2019006427A (es) Nuevos compuestos como agonistas peptidicos de receptores de glp1/glucagon/gip.
MX2018010640A (es) Co-agonistas del glucagon y de glp-1 para el tratamiento de la obesidad.
MX2020010004A (es) Composicion farmaceutica que comprende empagliflozina, metodos para tratamiento y sus usos.
EA028951B9 (ru) Пептидные конъюгаты агониста рецептора гастрина и глюкагон подобного пептида 1
MX2023000796A (es) Composicion farmaceutica, metodos para tratamiento y sus usos.
BR112013029256A2 (pt) "combinações farmacêuticas para uso no tratamento de pacientes com diabetes tipo 2, método de tratamento, e usos de lixisenatida e metformina".
PH12016500140A1 (en) Heterobicycloaryl rorc2 inhibitors and methods of use thereof
MX347372B (es) Uso de metformina en combinacion con un activador de glucoquinasa y composiciones que comprenden metformina y un activador de glucoquinasa.
MX2015008555A (es) Combinaciones de un agonista de glp1r y metformina, y uso de los mismos para el tratamiento de la diabetes tipo 2 y otros trastornos.
PH12017501290A1 (en) Treatment of pediatric type 2 diabetes mellitus patients with lixisenatide
EA201691567A1 (ru) Способы лечения легких травм головного мозга
MX2015005733A (es) Compuestos triciclicos para usarse en el tratamiento y/o control de obesidad.
EP2566502A4 (en) METHODS OF TREATING OR PREVENTING CARDIOVASCULAR DISORDERS AND PROVIDING CARDIOVASCULAR PROTECTION

Legal Events

Date Code Title Description
GB Transfer or rights

Owner name: VTV THERAPEUTICS LLC

HC Change of company name or juridical status

Owner name: KIMBERLY-CLARK WORLDWIDE, INC.

FG Grant or registration